Biointelect and CR2O forge new strategic partnership to provide advanced end-to-end commercialisation solutions for the life science sector globally

HomeResourcesBiointelect and CR2O forge new strategic partnership to provide advanced end-to-end commercialisation solutions for the life science sector globally
Driving more efficient and accelerated results from pre-clinical trials to commercialisation of new therapies for Australian, European and U.S. firms.

The full innovation journey offering for Biointelect, a strategic life science consulting company, and CR2O, a leading contract research organisation, has reached new heights, with Australian, European and U.S. clients now able to tap into world-class strategic advice and full-service clinical trial capabilities following the announcement of Biointelect’s and CR2O’s new strategic partnership.

Biointelect and CR2O will work to provide our clients solutions across geographical boundaries and rapidly navigate an increasingly complex regulatory, access, policy and clinical landscape. Based in the Netherlands, CR2O is expanding Biointelect’s existing capability to include clinical trial capabilities across the European Union and Australia. The partnership will give CR2O access to Biointelect’s strategic product development consultancy and commercialisation capabilities.

The transformational move puts Biointelect and CR2O at the forefront for providing world-class innovative end-to-end commercialisation solutions to streamline project work across every phase of the development cycle.

Biointelect CEO Leah Goodman said ultimately this collaborative partnership will mean strengthened confidence for clients in reaching their goals and an enhanced customer experience with a focus on performance.

“We are delighted that our partnership with CR2O enhances the full value Biointelect brings to our clients, completing our partnership capability from early research right through to commercialisation.”

“The alliance with CR2O will generate even greater returns for clients across the full innovation journey via a consolidated service offer with a trusted partner.”

“Biointelect’s reputation for quality is a common value with CR2O, and we are confident that together this global expansion will continue to enable our collaboration with Life science partners in enhancing the ecosystem and bringing innovation to patients,” Goodman added.

Trusted connections

The strategic partnership harnesses the deep insights, ground support and local presence of both CR2O and Biointelect for Australian, European and U.S. clients across the pharmaceutical and biotechnology industries.

Core to the advancement strategy is an understanding of the macroeconomic and geopolitical tensions that often impact the sector, to deliver fit-for-purpose clinical development solutions that de-risk the pathway to patient care settings.   

CR2O CEO Hadil Es-Sbai believes the partnership with Biointelect will strengthen strategic capabilities by leveraging established relationships with stakeholders to provide advanced end-to-end commercialisation solutions for clients.

“We are very pleased to strengthen our collaboration with Biointelect by leveraging their world-class strategic planning and commercialisation capabilities for the benefit of our pharmaceutical and biotechnology clients. Together we offer integrated, fit-for-purpose clinical development solutions that de-risk the complex journey from bench to bedside,” said Es Sbai.

Performance driven

The new partnership has ushered in a wave of enquiries from universities, government, biotechnology and pharmaceutical companies seeking a wholistic, one-stop-shop for tailored solutions across the full innovation journey. With a synergy in values underpinning the partnership’s success, both will leverage their proven track records to continue a trajectory of bringing life science innovations to market.   

“At the end of the day, our aim is to deliver outstanding results for our clients through an efficient and accelerated approach with a focus on reliability and credibility. Our partnership with CR2O enhances our ability to provide value to our now shared clients.” Goodman said.


Australia: Biointelect CEO Leah Goodman

With a career spanning executive leadership roles at Bristol-Myers Squibb, Merck Healthcare, and Sanofi, Leah has excelled in diverse therapeutic areas, from immunooncology to primary care.

She has significant experience successfully leading Multinational company business transformation and growth in Australia and across Asia including South East Asia, Korea, and Japan.

In November 2023, Leah commenced as Chief Executive Officer at Biointelect. Drawing on her extensive leadership background, she has embarked on successfully engaging the company to this new strategic vision and long-term success.

Netherlands: CEO CR2O Hadil Es-Sbai

Hadil is the founder of multiple successful service companies in the Life Sciences. He majored in analytical chemistry at the VU University Amsterdam and has since assumed several international clinical development roles within the pharmaceutical and clinical contract research industries. He became an entrepreneur in 2006 and has since combined several functions that are all related to innovation and business development in the pharmaceutical and clinical domain.

About Biointelect

Biointelect is a leading strategic planning and commercialisation advisory firm for the life science sector based in Australia. We harness our global 360° view of the healthcare ecosystem to provide a dynamic approach and expert advice at each stage of the development pathway to accelerate innovation for patients.

Biointelect enables the commercialisation of new therapies by helping clients to develop and drive integrated strategy, identify, and evaluate new business opportunities and engage with the right partners.

Founded in 2012, Biointelect channels the vision of co-founders Jennifer and Karl Herz to bring innovative science to market. The firm’s local and international experience across multiple areas within the life sciences sector places Biointelect at the forefront of advancing healthcare for all.

More information can be found at 

About CR2O

CR2O BV is a full service CRO for public organizations, biotech and pharma industries. CR2O combines strong scientific leadership and operational excellence to conduct innovative clinical trials. Over the past decade, CR2O built extensive experience managing complex clinical development programs and implementing phase I-IV clinical trials. CR2Os ecosystem integrates end-2-end expertise to advance new therapies from bench to bedside. The combined services of CR2Os different cross-functional experts accelerate product development planning. Our Non-Clinical, Clinical, CMC and Regulatory experts all have hands-on experience, capable of meeting your specific needs. Using CR2Os one-of-a-kind approach will de-risk product development processes and ensure generation of credible data sets.

More information can be found at

Media Contacts:


Ellemieke von Mauw

Sr Director Clinical Programs | Business Development at CR2O


Audrey Rollin

Senior Associate at Biointelect

Related Resources

Want To Find Out More?

Are you interested in learning more about Biointelect, including our current white paper submissions and health policy related work?

Get in touch with our team to discover how we’re advancing healthcare for all and how you can harness our intellect and proven expertise in bringing innovative life science to market.

Download Your PDF

To access the PDF, please fill out the form below. Once completed, you’ll be redirected to our folder where you can download all available resources.

Please enable JavaScript in your browser to complete this form.